EditorialMore genes, more problems? Benefits and risks of multiplex genetic testing☆
References (10)
- et al.
Linkage of early-onset familial breast cancer to chromosome 17q21
Science
(Dec 21 1990) - et al.
A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis
J. Natl. Cancer Inst.
(Feb 2 1994) - et al.
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Nat. Genet.
(Sep 2011) - et al.
Germline RAD51C mutations confer susceptibility to ovarian cancer
Nat. Genet.
(May 2012) - et al.
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
Nat. Genet.
(May 2010)
There are more references available in the full text version of this article.
Cited by (8)
The impact of the number of tests presented and a provider recommendation on decisions about genetic testing for cancer risk
2021, Patient Education and CounselingCitation Excerpt :In contrast, some genes confer moderately increased risks for cancer (e.g. ATM, CHEK2, BRIP1) and the link between positive results and downstream health outcomes is less clear. Testing for some moderate penetrance genes remains controversial in the community and efforts to better understand these genes and their clinical utility are ongoing [3,7–13]. There is a wide assortment of gene combinations available through various commercial labs and the composition of genes on these panels is largely unregulated in the United States [3].
Prevalence of mutations in a diverse cohort of 3162 women tested via the same multigene cancer panel in a managed care health plan
2020, Journal of Community GeneticsBreadth of genetic testing selected by patients at risk of hereditary breast and ovarian cancer
2018, International Journal of Gynecological CancerPreferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families
2018, Journal of Community GeneticsGermline testing for predisposition to breast/ovarian cancer should only be offered to selected patients with epithelial ovarian cancer
2017, Indian Journal of Gynecologic Oncology
View full text
Copyright © 2015 Published by Elsevier Inc.